BeyondSpring Pharma, a virtual US-China company, filed to stage a $100 million IPO on the NASDAQ exchange. The company’s business plan calls for integrating US and China clinical resources, making adept use of both to reduce cost and time. The company focuses on cancer-related therapies and plans to market them in the US and China. BeyondSpring will advance plinabulin as a treatment for neutropenia, and it is also testing the molecule, alone and as an adjunct to existing therapies, as a direct acting therapeutic for several forms of cancer.
